Proiriftrative Diabetic Retinopathy Clinical Trial
— PDROfficial title:
Comparison Between Result and Side Effects of Treatment of Prolifrative Diabetic Retinopaty by Conventional and Extended Targeted Pan Retinal Photocoagolation
| Verified date | October 2010 |
| Source | hahid Beheshti University of Medical Sciences |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Iran: Ethics commitee |
| Study type | Interventional |
Proliferative diabetic retinopathy (PDR) is treated with conventional pan retinal photocoagulation (PRP) which can improve the visual prognosis in this complication significantly. However , the treatment may also resulting adverse effects such as blurring of central vision, visual field constriction and disturbance in dark adaptation and contrast vision. Extended targeted retinal coagulation (TRP) to the ischemic areas may cause regression of the neovascularization while minimizing some of the risks and complication associated of treatment of PDR with these two methods.
| Status | Recruiting |
| Enrollment | 0 |
| Est. completion date | May 2011 |
| Est. primary completion date | April 2011 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - patients with PDR condidate for photocoagulation teraphy - Pupil with dilatasion=6mm - without privious treatment with anti VEGF drugs 3months before study - without privious vitroretinal sugery - without privoius lasertraphy Exclusion Criteria: - To have NVI cricteria with increase of inraocular pressure - to have cataract or vitrus leakage which prevent lasertraphy - pupil smaller that 6mm - traditional retinal detachment - privious treatment with anti VEGF drugs 3months before study - privious PRP - patient unable to get wide field FAG |
Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Iran, Islamic Republic of | Labbafinejad medical center | Tehran |
| Lead Sponsor | Collaborator |
|---|---|
| hahid Beheshti University of Medical Sciences |
Iran, Islamic Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | no leakage in widefield fluorescin angiography | 3 months after lasertraphy | No |